Search Results

November 2021 Twist Bioscience Launches Revelar Biotherapeutics to Develop and Commercialize Novel COVID offering of high-quality synthetic DNA using its silicon platform, today announced it has launched Revelar Biotherapeutics, Inc., an independently operated, new biotechnology company to develop and commercialize In addition, Revelar will have the ability to leverage the antibody discovery and optimization platform

October 2022 "Over three decades of research have provided thorough insights into G protein-coupled receptor (GPCR) regulation. In a recent issue of Molecular Cell, Fonseca et al. identified a previously overlooked desensitization mechanism. Agonist activation of the β2-adrenoceptor (β2AR) causes its S-nitrosylation that is required for the receptor to internalize and desensitize. Eliminating β2AR S-nitrosylation by mutation of C265 augments β2AR protein kinase A signaling, enables β2AR nitric oxide (NO) signaling, renders mice resistant to bronchoconstriction, and protects mice from allergen-induced asthma." Read more at the source #DrGPCR #GPCR #IndustryNews

The captured structures reveal a dynamic of conformational changes initiated by the binding of an agonist

< GPCR News < GPCRs in Oncology and Immunology Dynamic Phosphoproteomics of BRS3 Activation Reveals the Data analysis revealed that 27 phosphopeptides corresponding to six proteins were involved in the Hippo

< GPCR News < GPCRs in Oncology and Immunology Distinct Activation Mechanisms of CXCR4 and ACKR3 Revealed The data revealed that apo-CXCR4 preferentially populates a high-FRET inactive state, while apo-ACKR3

News < GPCRs in Oncology and Immunology Systems modeling of oncogenic G-protein and GPCR signaling reveals Modeling the two major, mutually-exclusive, oncogenic mutations (Gαq/11 and CysLT2R) revealed the potential